MOG Antibody-Associated Spinal Cord Inflammation Can Mimic Acute Flaccid Myelitis
Mayo Clinic researchers report that spinal cord inflammation associated with an antibody to myelin oligodendrocyte glycoprotein (MOG) can mimic acute flaccid myelitis, a rare but serious disease linked to certain viruses that particularly affects children and can result in paralysis. The researchers show that detecting the MOG antibody has important treatment and prognostic implications. The findings appear in JAMA Neurology.
The mimicry finding was an unexpected discovery, as the study focused on patients with transverse myelitis, a disease of spinal cord inflammation that also can lead to paralysis. MOG is a helpful biomarker of transverse myelitis, the researchers report.
Of 54 patients in the study, 19 percent with spinal cord inflammation from the MOG antibody were initially misdiagnosed with acute flaccid myelitis.
Patients with MOG antibodies may respond to steroids and additional treatments, such as plasma exchange to remove these antibodies from the blood, but acute flaccid myelitis does not respond well to such treatments.
“It is important for physicians to search for this MOG antibody in individuals who present with paralysis from spinal cord inflammation because the patients with MOG antibody respond well to treatment that lowers the immune system response,” says Eoin Flanagan, M.B., B.Ch., a Mayo Clinic neurologist and senior author of the article.
The nerves of the spinal cord are covered with an insulating layer called the myelin sheath, similar to insulation of an electrical wire. MOG is a part of this insulation system. “Patients who have the MOG antibody get inflammation that damages this insulation, with loss of signaling in the spinal cord resulting in paralysis,” says Divyanshu Dubey, M.B.B.S., a Mayo Clinic neurologist and first author of the article.
Testing for the MOG antibody also helps from a prognostic standpoint, Dr. Dubey says, because its presence helps predict patients who are more likely to relapse. In 2017, Mayo Clinic developed the MOG antibody test, the first of its kind in the United States.
Study limitations include the variability in treatments used, which prevented the researchers from determining which immune lowering treatment was best.